1. Scrip
  2. >>Business

Antifungal Specialist F2G Gets Near $61m Financing

Now Hopes For Early FDA Approval Of Lead Asset

 
• By Sten Stovall

A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.

Fungemia
Approval would make olorofim the first new antifungal treatment in 20 years • Source: Shutterstock

Equipped with nearly $61m in fresh finance, F2G Ltd can now progress its lead asset, olorofim, in a Phase IIb trial treating rare and resistant life-threatening invasive fungal infections, data from which might bring it early regulatory approval and make it the first new antifungal treatment in 20 years.

The UK- and Austria-based biotech, which is developing novel therapies for life-threatening systemic fungal infections, says it now has the financial resources needed to bring its lead asset through to pivotal trials – and potential accelerated approval – after the financing round closed on 12 August, raising a total of $60.8m

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.